Figure depicts a selection of property distributions of SAVI that are generally seen as important for drug design. The plots shown here are for the Plus subset of SAVI; values for the Negn" sets (plots are provided in sections 5, 6, 7 and 8 of the Supplementary Information 1 show similar distributions. These together with the additional properties provided in section 4 of the Supplementary Information 1, show that the SAVI product set is well suited for drug development. We note that the QED distribution is more drug-like than any of the databases analyzed in the original QED publication . Similarly, the Bruns & Watson demerits 79 are within the strict limit of <100 used at Eli Lilly in 41% of the Plus SAVI compounds, and within the looser Eli Lilly limit of <160 in 65% of the cases.